Wells Fargo
MDGL icon

Wells Fargo’s Madrigal Pharmaceuticals MDGL Stock Holding History

Wells Fargo’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9,100
Closed -$2.11M – 7632
2023
Q4 		$2.11M Sell
9,100
-8,200
-47% -$1.43M ﹤0.01% 2873
2023
Q3 		$2.53M Buy
+17,300
New +$3.26M ﹤0.01% 2619

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo's MDGL Position: Q1 2026 in Review

Wells Fargo reduced its Madrigal Pharmaceuticals (MDGL) stake by 26% in Q1 2026, selling an estimated $5.37M and leaving 32,212 shares worth $16.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1637.

Wells Fargo first reported a position in MDGL in Q2 2013 and has held it in 52 quarters since. The position peaked at $25.3M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Wells Fargo held 32,212 shares of Madrigal Pharmaceuticals worth $16.9M as of Q1 2026.
  • Wells Fargo sold 11,245 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $5.37M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #1637 holding.
  • Wells Fargo first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Madrigal Pharmaceuticals position peaked at $25.3M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.